Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05012397 · OUTCOME

Disease Control Rate (DCR)

Milademetan in Advanced/Metastatic Solid Tumors · Source last updated 2024-10-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
From first dose date to first CR, PR, or stable disease (SD) >= 16 weeks, or study completion date; up to 23.5 months

What was measured

DCR defined as the percentage of patients with confirmed CR, PR, or stable disease (SD) for ≥ 16 weeks

Analysis population: The efficacy analysis is conducted in all participants within the Centrally confirmed population (CCP).

Groups in this outcome

Milademetan (RAIN-32)

260 mg once daily (QD) orally on Days 1 to 3 and Days 15 to 17 of each 28-day cycle

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Milademetan (RAIN-32)31

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Milademetan (RAIN-32)22.6Not reported9.641.1Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        9.6
        upper Limit
        41.1
        value
        22.6
denoms
  1. counts
    1. group Id
      OG000
      value
      31
    units
    Participants
description
DCR defined as the percentage of patients with confirmed CR, PR, or stable disease (SD) for ≥ 16 weeks
dispersion Type
95% Confidence Interval
groups
  1. description
    260 mg once daily (QD) orally on Days 1 to 3 and Days 15 to 17 of each 28-day cycle
    id
    OG000
    title
    Milademetan (RAIN-32)
param Type
NUMBER
population Description
The efficacy analysis is conducted in all participants within the Centrally confirmed population (CCP).
reporting Status
POSTED
time Frame
From first dose date to first CR, PR, or stable disease (SD) >= 16 weeks, or study completion date; up to 23.5 months
title
Disease Control Rate (DCR)
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice